APA hamster model for diabetic atherosclerosis. 2. Analysis of lipids and lipoproteins.
Syrian hamsters of the APA strain (APA hamsters) have recently been shown to have atheromatous lesions in the aortic arches under diabetic condition induced by a single injection of streptozotocin (SZ). In that model, fatty streaks, which are the initial lesions of atherogenesis, develop by 6 weeks after the injection (WAI). In this study, we evaluated plasma lipid concentrations and lipoprotein profiles in diabetic APA hamsters at 6 WAI to reveal the early stage of atherogenesis clinicopathologically. As a result, by biochemical analysis, hyperglycemic APA hamsters showed signs of hypercholesterolemia and hypertriglyceridemia. Low-density lipoprotein (LDL) cholesterol significantly increased, but high-density lipoprotein (HDL) cholesterol significantly decreased. Agarose gel electrophoresis showed an obvious increase in the fractions of chylomicron, LDL and abnormal lipoprotein. Plasma LDL in diabetic animals was in a state more susceptible to oxidization. In addition, a significant increase in glycated LDL was also found in the diabetic animals by enzyme linked immunosorbent assay (ELISA). Moreover, lipid peroxidation product (4-hydroxynonenal (4 HNE))-adducted proteins and advanced glycation end-products (AGE) were immunohistochemically detected in the foam cells of the fatty streaks. These results revealed that diabetic APA hamsters had hyperlipidemia characterized by increases in chylomicron, LDL and abnormal lipoprotein, and suggested that oxidized LDL and/or glycated LDL might be actively uptaken by macrophages and play an important role in the initial stage of atherogenesis.
Yamanouchi
J
J
Department of Biomedical Science, Graduate School of Agricultural and Life Sciences, University of Tokyo, Japan.
Takatori
A
A
Itagaki
S
S
Kawamura
S
S
Yoshikawa
Y
Y
D000447:Aldehydes / Q000032:analysis; D000818:Animals; D001018:Aortic Diseases / Q000097:blood* / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood* / Q000473:pathology; D008078:Cholesterol, LDL / Q000097:blood; D006224:Cricetinae; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000473:pathology; D003925:Diabetic Angiopathies / Q000097:blood* / Q000473:pathology; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005487:Foam Cells / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000032:analysis; D007150:Immunohistochemistry; D015227:Lipid Peroxidation; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male
D000447:Aldehydes; D008078:Cholesterol, LDL; D017127:Glycation End Products, Advanced; D008055:Lipids; D008074:Lipoproteins; C027576:4-hydroxy-2-nonenal